PDE4A and idiopathic pulmonary fibrosis: After establishing a therapeutic benefit of roflumilast and Compound 1 in reducing type II AEC‐injury‐induced fibrosis, we next compared the efficacy of PDE4 inhibition to treatment with the two FDA‐approved drugs for IPF (pirfenidone and nintedanib).